{"TopicDetails": {"type": 0, "ccm2Id": 45032531, "cftId": 0, "identifier": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01", "title": "Promoting implementation of research results into policy and practice", "publicationDateLong": 1652227200000, "callIdentifier": "HORIZON-JU-GH-EDCTP3-2022-01", "callTitle": "Research and Innovation actions supporting the global health EDCTP3 Joint Undertaking", "callccm2Id": 45032759, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["aids", "tuberculosis", "clinical trials", "HIV", "poverty-related diseases", "Africa", "implementation research", "re-emerging infectious diseases", "sub-Saharan Africa", "malaria", "respiratory infection", "febrile illness", "health", "antimicrobial resistant infection", "emerging infectious diseases", "diarrhea", "health systems", "neglected infectious diseases", "infectious diseases", "global health"], "keywords": ["Social Innovation", "Health inequalities", "Global health", "Clinical trials", "Social sciences and humanities", "Africa", "Health sciences", "Prevention and treatment of infection by pathogens", "Health policies", "Health promotion", "Societal Engagement", "Infectious diseases", "International Cooperation"], "flags": ["SocInnov", "SSH", "Africa", "SocietalEngagement", "EC-WORLD"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "11 May 2022", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["30 August 2022"]}], "latestInfos": [{"approvalDate": "Oct 7, 2022 10:57:19 AM", "lastChangeDate": "Oct 7, 2022 10:57:19 AM", "content": "<p><span lang=\"EN-IE\" style=\"font-size: 10.5pt; line-height: 107%; font-family: &quot;inherit&quot;, serif; color: rgb(51, 51, 51); border: 1pt none windowtext; padding: 0cm;\">Call </span><span lang=\"EN-IE\">HORIZON-JU-GH-EDCTP3-2022-01</span><span lang=\"EN-IE\" style=\"font-size: 10.5pt; line-height: 107%; font-family: &quot;inherit&quot;, serif; color: rgb(51, 51, 51); border: 1pt none windowtext; padding: 0cm;\"> closed on 30 August 2022. A total of 92 proposals were submitted. The breakdown per topic is:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01: 40 proposals&nbsp;</span><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&#10;&quot;inherit&quot;,serif;mso-bidi-font-family:Calibri;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:FR-BE\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02: 14 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03: 20 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04:&nbsp; 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05: 16 proposals<o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:10.5pt;line-height:107%;font-family:&quot;inherit&quot;,serif;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:&#10;&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:FR-BE;mso-bidi-language:AR-SA\">Evaluation results are expected to be communicated on Friday 21 November 2022 at the earliest.</span></p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3418887": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 5000000}, "expectedGrants": 8, "minContribution": 600000, "maxContribution": 600000, "budgetTopicActionMap": {}}], "3418889": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 1000000}, "expectedGrants": 1, "minContribution": 1000000, "maxContribution": 1000000, "budgetTopicActionMap": {}}], "3418891": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 30850000}, "expectedGrants": 5, "minContribution": 6000000, "maxContribution": 8000000, "budgetTopicActionMap": {}}], "3418893": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 22000000}, "expectedGrants": 4, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}], "3418895": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 38030000}, "expectedGrants": 9, "minContribution": 4000000, "maxContribution": 4000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2022"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>This topic aims at supporting activities that contribute to one or several of the expected impacts for this call. To that end, proposals under this topic should aim for delivering results that are contributing to the following expected outcomes:</p><ul level=\"0\"><li>Uptake of research results into clinical practice so that people in sub-Saharan Africa, particularly vulnerable populations, can have access to safe health technologies<sup><a target=_self href=#fn1 id=r1>[1]</a></sup> of proven efficacy for poverty-related diseases, including emerging and re-emerging infectious diseases and antimicrobial resistant infections;</li><li>Operational and evaluation tools for successfully translating research results into clinical practice are validated and health systems in sub-Saharan Africa are improved;</li><li>Widespread adoption of research results into national and international policy guidelines.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>Failure to translate research findings into policy and practice prevents research from achieving maximum public health benefit. Despite substantial investment in clinical research in poverty-related diseases, including emerging and re-emerging infectious diseases and antimicrobial-resistant infections, exploitation and use of results beyond research groups to date remains limited. The barriers to an efficient uptake of research results include limited interaction between researchers, policymakers, patients\u2019 community and other stakeholders, lack of experience in exploiting research results beyond academia, limited health systems capacity, affordability issues, and structural and cultural differences between the realms of research, programme planning and policymaking.</p><p>Proposals should address the following activities:</p><ul level=\"0\"><li>Carry out registration and/or post-registration studies of health technologies (such as pragmatic effectiveness studies) that address diseases within the scope of GH EDCTP3 to demonstrate the clinical effectiveness in relevant patient populations;</li><li>Demonstrate the cost effectiveness of the health technologies being investigated in relevant communities;</li><li>Identify barriers to uptake of the health technologies being investigated and address them in the studies to be carried out;</li><li>Develop methods and evaluation tools that can ensure translating clinical research results into healthcare policy and practice. These methods should be broadly applicable to improve patients quality of life beyond the specific health technology being investigated;</li><li>Early involvement and regular interaction with policy and decision makers as well as end-users to have the health technology adopted by health systems.</li> </ul><p>Applicants need to concisely describe any prior research findings and explain how the proposal builds on these results. Building on results from projects supported under previous EDCTP programmes is encouraged.</p><p>Proposals should present a sound assessment of the feasibility of the proposed work, especially as regards the planned clinical investigations. Realistic plans for recruiting trial subjects should be presented and corroborated by demonstrated success from previous studies. The proposals should justify the choice of populations to be enrolled into the trials and explain how they relate to the larger population. The full range of relevant determining characteristics (sex, gender, age, socio-economic status, etc.) needs also to be considered.</p><p>Proposals should describe how stakeholder views of the proposal\u2019s relevance and the study design have been incorporated in the co-creation process of planning the research proposal. Proposals should indicate explicit plans for good participatory practices for engaging stakeholders at every step of the research life-cycle.</p><p>Proposals should provide details on the methodology for linking clinical research aspects with the translation into healthcare practice and policy.</p><p>Applicants are welcome to draw on any relevant lessons from knowledge translation in response to the COVID-19 pandemic.</p><p>It is essential that proposals bring together clinical researchers with experience in implementation research, health policy experts and end users.</p>\n<SPAN class=\"topicdescriptionkind\">Cross-cutting Priorities</SPAN>:<p>Social sciences and humanities<br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=EC-WORLD;sortQuery=sortStatus;orderBy=asc\">International Cooperation</a><br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=SocietalEngagement;sortQuery=sortStatus;orderBy=asc\">Societal Engagement</a><br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=SocInnov;sortQuery=sortStatus;orderBy=asc\">Social Innovation</a><br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=Africa;sortQuery=sortStatus;orderBy=asc\">Africa</a><br></p>\n<p id=fn1><a  target=_self href=#r1>[1]</a>The definition of health technology is the application of organized knowledge and skills in the form of medicines, medical devices, vaccines, procedures and systems developed to solve a health problem and improve quality of life.</p>", "conditions": "<p><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:115%;&#10;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:&#10;Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;color:#404040;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:EN-US;&#10;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">General conditions</span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;&#10;mso-bidi-font-weight:bold\">described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex A</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> and </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex E</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> of the Horizon Europe Work Programme General Annexes</span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\"> described in Part B of the Application Form available in the Submission System</span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\n<p><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">2. Eligible countries:&nbsp;</span></b></p>\r\n<p><span lang=\"EN-US\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:&#10;minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">According to Article 110 of the Council Regulation (EU) 2021/2085, funding from the&nbsp; Global Health EDCTP3 Joint Undertaking is restricted to legal entities established in Member States or associated countries or in the constituent states of the EDCTP Association.</span></p>\r\n<p><span lang=\"EN-US\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:&#10;minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Constituent states of the EDCTP Association that are not Member States or associated countries are: Burkina Faso, Cameroon, Congo, C&ocirc;te d&rsquo;Ivoire, Ethiopia, Gabon, The Gambia, Ghana, Kenya, Mali, Mozambique, Niger, Nigeria, Senegal, South Africa, Tanzania, Uganda, United Kingdom, Zambia.</span></p>\r\n<p><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\">Horizon Europe Programme Guide</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\">.</span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">3<span style=\"mso-bidi-font-weight:bold\">. Other eligibility conditions:</span></span></b><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\"> described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex B</a></span></span><span style=\"mso-ansi-language:EN-US\"> <span lang=\"EN-US\">of the Work Programme General Annexes,&nbsp;</span></span>except for the specific conditions for GH EDCTP3 funding as regards <u>Entities eligible for funding</u> and <u>Consortium composition.</u></p>\r\n<p class=\"MsoNormal\"><i><u><span lang=\"EN-IE\">Entities eligible to participate<o:p></o:p></span></u></i></p>\r\n<p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-IE\">Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government controlled territories of Ukraine. Therefore, such legal entities are not eligible to participate in any capacity. This criterion also applies in cases where the action involves financial support given by grant beneficiaries to third parties established in Russia, Belarus or in non-government controlled territories of Ukraine (in accordance with Article 204 of the Financial Regulation No 2018/1046).<b><u><o:p></o:p></u></b></span></p>\r\n<p class=\"MsoNormal\"><i><u><span lang=\"EN-IE\">Entities eligible for funding<o:p></o:p></span></u></i></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\">To be eligible for funding, applicants must be eligible to participate and established in one of the eligible countries, i.e.<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-indent:-18.0pt;line-height:105%;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"EN-IE\">-<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\">The Member States of the European Union, including their outermost regions;<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-indent:-18.0pt;line-height:105%;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"EN-IE\">-<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\">The Oversees Countries and Territories (OCTs) linked to Member States<a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftn1\" name=\"_ftnref1\" title=\"\"><span class=\"MsoFootnoteReference\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[1]</span></span><!--[endif]--></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-indent:-18.0pt;line-height:105%;&#10;mso-list:l0 level1 lfo1\"><!--[if !supportLists]--><span lang=\"EN-IE\">-<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\">Eligible non-EU countries:<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:72.0pt;text-indent:-18.0pt;&#10;line-height:105%;mso-list:l0 level2 lfo1\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-family:&quot;Courier New&quot;;mso-fareast-font-family:&quot;Courier New&quot;;&#10;mso-ansi-language:EN-IE\">o<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\">Countries associated to Horizon Europe<a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftn2\" name=\"_ftnref2\" title=\"\"><span class=\"MsoFootnoteReference\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[2]</span></span><!--[endif]--></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left:72.0pt;text-indent:-18.0pt;&#10;line-height:105%;mso-list:l0 level2 lfo1\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-family:&quot;Courier New&quot;;mso-fareast-font-family:&quot;Courier New&quot;;&#10;mso-ansi-language:EN-IE\">o<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\">Countries that are members of the EDCTP Association<a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftn3\" name=\"_ftnref3\" title=\"\"><span class=\"MsoFootnoteReference\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[3]</span></span><!--[endif]--></span></a><o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call conditions, or if the participation is considered essential for implementing the action by the granting authority.</span></p>\r\n<div><!--[if !supportFootnotes]--><br clear=\"all\" />\r\n<hr align=\"left\" size=\"1\" width=\"33%\" />\r\n<!--[endif]-->\r\n<div id=\"ftn1\">\r\n<p class=\"MsoFootnoteText\"><a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftnref1\" name=\"_ftn1\" title=\"\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\" style=\"font-size:10.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-US;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[1]</span></span><!--[endif]--></span></span></a><span lang=\"EN-US\"> </span><span lang=\"EN-IE\">Entities from Oversees Countries and Territories (OCT) are eligible for funding under the same conditions as entities from the Member State to which the OCT in question is linked. See the </span><span lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span lang=\"EN-IE\">Horizon Europe Programme Guide</span></a></span><span lang=\"EN-IE\"> for a complete list of OCTs.</span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n</div>\r\n<div id=\"ftn2\">\r\n<p class=\"MsoFootnoteText\"><a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftnref2\" name=\"_ftn2\" title=\"\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\" style=\"font-size:10.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-US;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[2]</span></span><!--[endif]--></span></span></a><span lang=\"EN-US\"> </span><span lang=\"EN-IE\">See list of </span><span lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf\"><span lang=\"EN-IE\">Associated Countries</span></a></span><span class=\"MsoHyperlink\"><span lang=\"EN-IE\"> and <a href=\"https://ec.europa.eu/info/research-and-innovation/strategy/strategy-2020-2024/europe-world/international-cooperation_en\" target=\"_blank\">International Cooperation</a></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n</div>\r\n<div id=\"ftn3\">\r\n<p class=\"MsoFootnoteText\"><a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftnref3\" name=\"_ftn3\" title=\"\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\"><!--[if !supportFootnotes]--><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\" style=\"font-size:10.0pt;line-height:&#10;107%;font-family:&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-ansi-language:EN-US;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">[3]</span></span><!--[endif]--></span></span></a><span lang=\"EN-US\"> </span><span lang=\"EN-IE\">See the </span><span lang=\"EN-US\"><a href=\"http://www.edctp.org/about-us/governance/general-assembly/members-of-the-general-assembly/\"><span lang=\"EN-IE\">EDCTP website</span></a><o:p></o:p></span></p>\r\n</div>\r\n</div>\r\n<p>&nbsp;</p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b>4. Financial and operational capacity and exclusion: </b><span style=\"mso-bidi-font-weight:bold\">described in <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex C</a> of the Work Programme General Annexes</span></p>\r\n<p>&nbsp;</p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\" style=\"mso-ansi-language:FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\r\n<p>&nbsp;</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Award criteria&nbsp;</span></b><span lang=\"EN-US\">&nbsp;are      described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      D</a></span><span lang=\"EN-US\"> of      the Work Programme General Annexes.</span></li>\r\n    <li class=\"MsoNormal\">\r\n    <p class=\"MsoNormal\"><strong><span lang=\"EN-US\">Scoring and thresholds</span></strong><span lang=\"EN-US\"> are as follows:<o:p></o:p></span></p>\r\n    <p class=\"MsoNormal\" style=\"text-align:justify\"><span lang=\"EN-IE\">Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.<o:p></o:p></span></p>\r\n    <span lang=\"EN-IE\" style=\"font-size:11.0pt;line-height:107%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-IE;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\">Proposals that pass the individual threshold AND the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.</span><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      F</a></span><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\">Online      Manual</a><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      F</a></span><span lang=\"EN-US\"> of the Work Programme General Annexes</span><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex G</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\"> of the Work Programme General Annexes<o:p></o:p></span></p>\r\n<p>&nbsp;</p>\n<p>Implementing the provision on affordable access as defined in Article 114 of the 2021/2085 Council Regulation establishing the Joint Undertakings under Horizon Europe[[Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17]], grants award under this topic will have to submit the following deliverables:</p><p>1. Stewardship plan</p><p>Beneficiaries must prepare stewardship plans outlining how to achieve the optimal use of an intervention, including, for example, how to avoid irrational use, overuse or abuse of health technologies (e.g. antimicrobials). A draft plan must be submitted after half the duration of the project has elapsed and a final plan must be submitted with the final report.</p><p>2. Global access plan</p><p>With the final report, beneficiaries must submit an appropriate and proportionate global access plan that covers registration targets, plans to meet demand, flexible approaches to IP and other strategies that reflect ability to pay and ensure that economic barriers to access are low.</p>\n<p>Also in line with Article 114 of the 2021/2085 Council Regulation<u>, </u>participants will be subject to the following additional exploitation obligations:</p><ol level=\"0\">  <li>Participants must \u2013 up to four years after the end of the action (see Data Sheet, Point 1) \u2013 use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants\u2019 best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.</li><li>In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non-exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.</li> </ol><p>In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.</p><p>For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product or any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.</p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\">Specific conditions<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme<o:p></o:p></span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\">Documents<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">Call documents:<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard application form &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia_en.pdf\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\">Standard application form (HE RIA, IA)</span></a><span style=\"color:#404040;mso-themecolor:&#10;text1;mso-themetint:191;mso-ansi-language:EN-US;mso-bidi-font-weight:bold\"> <span lang=\"EN-US\"><o:p></o:p></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">Standard evaluation form </span><span lang=\"EN-US\">&mdash;<i> will be used with the necessary adaptations</i></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-ria-ia_en.pdf\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard evaluation form (HE RIA, IA)</span></a><span lang=\"EN-US\" style=\"color:#404040;&#10;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color: rgb(64, 64, 64);\">MGA</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;tab-stops:&#10;191.4pt\"><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\">HE <span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">General MGA v1.1</span></a></span></span><span class=\"MsoHyperlink\"><span style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> <span lang=\"EN-US\"><o:p></o:p></span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;tab-stops:&#10;191.4pt\"><span style=\"color: rgb(64, 64, 64);\">Call-specific instructions</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US;mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\">Information on clinical studies (HE)</a>&nbsp;<o:p></o:p></span><span style=\"background-color: rgb(198, 219, 239); font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px;\">(only for proposals including clinical studies)</span></p>\r\n<p>&nbsp;</p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\">Additional documents:</span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/sites/default/files/research_and_innovation/research_by_area/documents/ec_rtd_global-health-edctp3-wp-annex1.pdf\" target=\"_blank\">GH EDCTP3 JU Work Programme 2022</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">HE Main Work Programme 2021&ndash;2022 &ndash; 13. General Annexes</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<ul>\r\n    <li><a href=\"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.L_.2021.427.01.0017.01.ENG&amp;toc=OJ%3AL%3A2021%3A427%3ATOC\" target=\"_blank\">GH EDCTP3 JU Regulation of Establishment</a></li>\r\n    <li><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\">HE Programme guide</a></li>\r\n    <li><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\">HE Framework Programme and rules for Participation Regulation&nbsp; 2021/695</a></li>\r\n    <li><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\">HE Specific Programme Decision 2021/764</a></li>\r\n    <li><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\" target=\"_blank\">EU Financial Regulation</a></li>\r\n</ul>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><o:p></o:p></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\">Funding &amp; Tenders Portal Terms and Conditions</a><o:p></o:p></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\">Funding &amp; Tenders Portal Privacy Statement</a></span></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><b>Online Manual&nbsp;</b></a></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><strong><u><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span></u></strong><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "", "staticAdditionalInfo": "<p>The general conditions relating to this call are those applicable to the 2021/2022 work programme of Global Health EDCTP3 outlined above.</p><p><u>Expected impacts of Call 1</u></p><p>Activities funded under this call for proposals should contribute to:</p><ul level=\"0\"><li>Achieve SDG3 \u2018Ensure healthy lives and promote well-being for all at all ages\u2019 in sub-Saharan African countries;</li><li>Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;</li><li>Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;</li><li>Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;</li><li>Enable countries in sub-Saharan Africa to better understand pathogen epidemiology and support effective public health monitoring through integration of genomics and epidemiology;</li><li>Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;</li><li>Strengthen health systems to ensure uptake of effective health technologies and innovations;</li><li>Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.</li> </ul>\n", "latestInfos": [{"approvalDate": "Dec 22, 2022 8:21:02 AM", "lastChangeDate": "Dec 22, 2022 8:21:02 AM", "content": "<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Information for the Funding Portal<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number proposals submitted: 92<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number Ineligible proposals: 11<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number proposals evaluated: 81<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Below threshold: 36<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Above threshold: 45<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Main list: 26<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Reserve list: 4<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number rejected due to budgetary ressources: 15<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number of proposal upgraded from Reserve list to Main list: 1</span></b><span lang=\"EN-IE\"><o:p></o:p></span></p>"}, {"approvalDate": "May 17, 2022 4:30:46 PM", "lastChangeDate": "May 17, 2022 4:30:46 PM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05(HORIZON-JU-CSA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}